Visby Medical has expanded access to its FDA-authorized at-home Women’s Sexual Health Test through new distribution agreements with Quest Diagnostics and Labcorp. The palm-sized PCR-based test, which detects chlamydia, gonorrhea, and trichomoniasis in 30 minutes, will now be available via Quest’s questhealth.com platform and Labcorp’s Labcorp OnDemand service. The move positions Visby’s test within a broader consumer health ecosystem, pairing diagnostics with same-day treatment pathways and further normalizing at-home STI testing for women.

What this expansion reveals about the shifting dynamics of STI diagnostics and women’s health autonomy

This announcement is less about a product launch and more about strategic infrastructure—the embedding of a next-generation diagnostic into two of the most widely used consumer lab access platforms in the United States. Visby Medical’s test is not new to the market, having secured FDA authorization and launched nationally in November 2025. What has changed is its accessibility: being listed on questhealth.com and Labcorp’s platforms adds institutional legitimacy, expands insurance and employer touchpoints, and repositions Visby from a standalone innovation to a plug-in component of mainstream women’s health access.

Unlike typical at-home STI tests that require sample shipment and multi-day result times, Visby’s PCR-based model delivers results in 30 minutes without leaving the house. That shifts not just the timeline but also the diagnostic model itself—from test-and-wait to test-and-treat, with integrated pathways for same-day virtual consultation and prescription access. Industry observers note this creates a fundamentally different risk-management profile for conditions like chlamydia and trichomoniasis, where early treatment can prevent downstream complications such as pelvic inflammatory disease or infertility.

The expansion also comes at a time when self-directed diagnostic tools are increasingly seen as a public health lever. Silent STI infections, especially among women, often go undetected due to stigma, logistical barriers, or lack of symptoms. By removing friction from the testing process and embedding it within platforms like Ovia Health, which already has a footprint among employers and health plans, Visby could help normalize sexual health diagnostics alongside fertility tracking and prenatal care.

Why the “instrument-free PCR” model may matter more than just convenience

Visby’s test is not a lateral move from existing rapid diagnostics; it is a new category. The device is fully self-contained and uses real-time PCR without requiring lab equipment or mobile device integration. This matters clinically because PCR remains the gold standard in terms of sensitivity and specificity for STI detection—yet until now has required centralized labs or professional oversight. Visby’s single-use format sidesteps the delays and sample degradation risks associated with mail-in models while delivering PCR-level accuracy in minutes.

Clinicians tracking the space suggest this could have important implications for test-of-cure strategies and public health reporting. A self-contained test that gives high-fidelity results in a short time frame could enable more responsive partner notification protocols and better data on reinfection trends, especially in underserved populations.

That said, the full diagnostic pathway still relies on external elements—patients must interpret results correctly, follow through with treatment, and potentially report positive cases to providers or health departments. The question becomes not whether the test works, but whether the surrounding systems—telehealth, prescription access, data interoperability—can keep pace with a 30-minute diagnostic cycle.

What Labcorp and Quest’s participation signals about consumer diagnostics strategy

The endorsement by Quest Diagnostics and Labcorp is significant in that both companies have been cautious but deliberate in their expansion into direct-to-consumer health services. Their inclusion of Visby’s test on consumer platforms is not merely an e-commerce decision—it signals internal alignment with the direction of decentralized diagnostics.

For Quest, the move broadens its sexual health testing menu beyond lab-based options, offering greater immediacy and convenience. Quest’s statement frames the partnership in terms of “illuminating a path to good health,” but the business logic also includes higher margin consumer services and enhanced brand equity in women’s health.

Labcorp’s alignment is perhaps even more strategic. By integrating Visby’s solution into Ovia Health—a digital platform focused on the reproductive health continuum—Labcorp gains a foothold in longitudinal care pathways that extend beyond episodic diagnostics. For employer clients and health plans, this could enable bundled offerings where STI testing, pregnancy planning, and remote monitoring tools coexist in a single workflow.

Still, integration is not implementation. As these platforms scale, questions will emerge around user comprehension, device disposal, reimbursement parity with lab-based tests, and how payers handle claims for home-based diagnostics that bypass traditional provider encounters.

What regulatory and clinical stakeholders will be watching next

The Visby device was already FDA-authorized, so this expansion does not introduce new regulatory uncertainty in itself. However, broader adoption through Quest and Labcorp will inevitably invite closer scrutiny from health systems, payers, and public health authorities. Specifically, stakeholders will likely evaluate:

Whether rapid at-home testing leads to earlier treatment initiation and improved clinical outcomes.

How false positives or negatives compare with lab-based PCR results in a real-world setting.

The public health reporting implications of a widely distributed home-based diagnostic that can operate without a physician.

Additionally, regulators may monitor whether the “test-to-treat” loop closes effectively or leaves patients in diagnostic limbo, particularly in states with more restrictive telemedicine or prescription laws. While Visby offers same-day care options via third-party vendors, execution will depend heavily on regional policy, health literacy, and digital access.

Risks, gaps, and what could undermine broader adoption

Despite its strengths, the Visby model faces several risks as it moves into mass-market channels. One is cost—PCR accuracy comes with higher per-unit pricing than lateral flow assays, which may inhibit uptake among uninsured users or those in high-burden regions without reimbursement support.

Another is behavioral adherence. While the device is designed for simplicity, self-collection still introduces error risk, and the absence of provider interpretation could lead to under- or overtreatment, especially if users misread results or forgo follow-up care.

A subtler risk is overextension. Visby’s value lies in being clinically rigorous yet operationally simple. As the company works to build a broader test menu or pursue international expansion, there’s a danger of diluting its core differentiator by competing with consumer-first wellness tests that lack regulatory and clinical weight.

Industry observers also caution that without clear data on test uptake and outcome tracking, it will be difficult to assess impact. In the long term, integrating Visby’s platform with EHR systems or public health databases could help bridge this gap—but doing so without compromising privacy or autonomy will be a key challenge.

  at-home diagnostics, chlamydia, FDA-authorized tests, gonorrhea, Labcorp, Ovia Health, PCR STI test, Quest Diagnostics, sexual health, trichomoniasis, Visby Medical, Women’s Sexual Health Test